Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

What is Intellia Therapeutics, Inc.?

A clinical-stage gene editing company, Intellia Therapeutics Inc. (NASDAQ: NTLA) focuses on CRISPR-based therapies. The market for genomics stocks is showing growth, with companies like NTLA, EDIT, and PRME shaping the future of medicine and biotech.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.1% on Aug 1, 2025 15:21

• The bearish movement in NTLA stock may be linked to an investigation alert by Bragar Eagel & Squire, P.C., raising investor concerns and leading to selling pressure.
• The market sentiment may have been negatively impacted by inducement grants reported by Intellia Therapeutics, as investors may have reservations about their effects on the company's financials.
• An upcoming conference call to discuss second-quarter earnings and company updates could have created uncertainty among investors, prompting a more cautious approach towards the stock.
• Despite the positive outlook for genomics stocks overall, recent news related to Intellia Therapeutics appears to have dampened industry prospects, resulting in the bearish movement of NTLA stock.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )

CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new ...

https://www.globenewswire.com/news-release/2025/08/01/3125715/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Intellia Therapeutics ( NASDAQ:NTLA )

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia ( NTLA ) To Contact Him Directly To Discuss Their Options

https://www.benzinga.com/pressreleases/25/07/g46779210/intellia-investigation-alert-bragar-eagel-squire-p-c-is-investigating-intellia-therapeutics-inc-on

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

CAMBRIDGE, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in ...

https://www.globenewswire.com/news-release/2025/07/31/3124878/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Second-Quarter-2025-Earnings-and-Company-Updates.html

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates - Intellia Therapeutics ( NASDAQ:NTLA )

CAMBRIDGE, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. NTLA, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference ...

https://www.benzinga.com/pressreleases/25/07/g46752441/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2025-earnings-and-company-

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...

https://www.zacks.com/stock/news/2638574/3-genomics-stocks-worth-adding-to-your-portfolio-in-2025

Trending Today

Bitcoin Cash ($BCH) Crypto Forecast: Down 5.4% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Amazon.com Inc. ($AMZN) Stock Forecast: Down 8.2% Today

Pacific Gas & Electric Co. ($PCG) Stock Forecast: Up 2.2% Today

LyondellBasell Industries NV Class A (Netherlands) ($LYB) Stock Forecast: Down 6.8% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 7.4% Today

Avantor, Inc. ($AVTR) Stock Forecast: Down 17.0% Today

Ethena ($ENA) Crypto Forecast: Down 5.2% Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 15.8% Today

Intellia Therapeutics, Inc. Price History

30.04.2025 - NTLA Stock was down 5.8%

• NTLA stock saw a notable decrease following reports of an individual experiencing adverse effects in its gene therapy trial, particularly linked to elevated liver enzymes.
• The downward trend in the stock could be connected to worries regarding the safety and effectiveness of Intellia's gene therapy contender, nex-z, for addressing ATTR-CM.
• Investors might be responding to the possible setbacks in Intellia's phase III trial, causing a loss of faith in the company's future role in the gene therapy industry.
• This incident underscores the risks and fluctuations inherent in biotech stocks, where the outcomes of clinical trials can profoundly influence stock performance.

16.04.2025 - NTLA Stock was up 5.4%

• The FDA approval for Incyte's drug Zynyz in a new cancer indication may have positively influenced the overall sentiment in the biotechnology sector, which includes companies like Intellia Therapeutics.
• Optimistic projections from Wall Street analysts indicating a significant upside in NTLA stock likely played a role in the bullish movement, with investors responding to growth potential.
• Positive industry developments and favorable analyst forecasts may have boosted investor confidence in Intellia Therapeutics, contributing to the strong bullish movement in the stock.

13.04.2025 - NTLA Stock was down 6.5%

• Despite reporting a narrower loss than expected in Q1 and surpassing revenue estimates, NTLA experienced a bearish movement.
• Investors might have been expecting even stronger results, leading to a sell-off after the earnings release.
• The market may have reacted negatively to any cautious guidance or concerns raised during the earnings call, overshadowing the positive financial metrics.
• It's possible that profit-taking occurred as some investors locked in gains following the recent stock price increase, despite the positive news about the company's pipeline and financials.

21.04.2025 - NTLA Stock was down 5.1%

• The decline in Intellia Therapeutics (NTLA) could be due to investors taking profits following a period of strong performance.
• Investor attention may have shifted to other biotech companies after FDA approval was granted for Zynyz in a new cancer indication for Incyte, prompting a sell-off in NTLA.
• High price targets set by Wall Street analysts, predicting a 408.6% increase in NTLA, might have raised concerns about the stock being overvalued, leading some investors to sell their shares.
• The bearish trend in NTLA appears to stem from a mix of profit-taking, changing investor focus, and potential worries about the stock's valuation based on analyst forecasts.

01.07.2025 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock may be linked to an investigation alert by Bragar Eagel & Squire, P.C., raising investor concerns and leading to selling pressure.
• The market sentiment may have been negatively impacted by inducement grants reported by Intellia Therapeutics, as investors may have reservations about their effects on the company's financials.
• An upcoming conference call to discuss second-quarter earnings and company updates could have created uncertainty among investors, prompting a more cautious approach towards the stock.
• Despite the positive outlook for genomics stocks overall, recent news related to Intellia Therapeutics appears to have dampened industry prospects, resulting in the bearish movement of NTLA stock.

08.04.2025 - NTLA Stock was up 5.2%

• NTLA experienced a significant bullish trend today, possibly driven by its exceeding revenue expectations by 14.67% in the first quarter.
• Investor sentiment towards NTLA appears positive post the earnings surprise, hinting at growth opportunities and market trust in the company's gene editing treatments.
• The market's reaction suggests that investors are interpreting NTLA's financial performance as a promising sign for its near-term trajectory.

08.06.2025 - NTLA Stock was up 5.8%

• Stock of Intellia Therapeutics has risen by 29.8% over the previous month, propelled by advancements in its gene therapy pipeline and growing investor attention.
• The recent FDA approval of Ekterly by KalVista Pharmaceuticals, the first oral on-demand treatment for HAE, is believed to have positively impacted confidence in the biotech sector, which includes NTLA.
• Encouraging updates on gene therapy progress and FDA approvals within the biotech industry may have influenced the strong bullish movement in NTLA today.
• Investors seem to be hopeful about the potential expansion and innovation in the gene editing and biopharmaceutical industries, resulting in heightened buying interest for companies like Intellia Therapeutics.

29.04.2025 - NTLA Stock was down 23.7%

• The investigation may have raised concerns among investors about potential legal issues or regulatory challenges for Intellia Therapeutics.
• The uncertainty surrounding the investigation could have led to a loss of confidence in the company's future prospects, resulting in a bearish movement in NTLA stock.
• Investors may be closely monitoring any developments related to the investigation and awaiting further clarity before making investment decisions in Intellia Therapeutics.

16.04.2025 - NTLA Stock was up 6.5%

• Analysts have a positive outlook on NTLA, with a mean price target indicating a potential upside of 408.63%.
• In Q1 2025, Intellia Therapeutics reported a narrower loss than expected and shared encouraging updates on its pipeline candidates, resulting in a surge in its stock price.
• The optimistic analyst forecasts and strong company performance likely contributed to today's bullish movement in NTLA's stock.

05.05.2025 - NTLA Stock was down 5.1%

• Beam Therapeutics' gene-editing therapy for sickle cell disease gaining orphan drug status from the FDA resulted in a surge in BEAM stock.
• Despite Wall Street analysts projecting a potential 398.3% upside for Intellia Therapeutics, the stock still experienced a bearish movement.
• Intellia's stock decline could be linked to a patient in its phase III study encountering adverse events, which impacted the company's gene therapy candidate and investor sentiment.
• The gene-editing sector's competition, notably with CRISPR advancing its in vivo pipeline, contributes to the intricate market dynamics affecting Intellia's stock performance.

27.05.2025 - NTLA Stock was up 6.5%

• NTLA's positive developments in its CRISPR/Cas9-based therapies could be driving its bullish movement, indicating progress in its pipeline.
• Investor interest in NTLA may have been sparked by comparisons with CRISPR Therapeutics (CRSP), leading to the uptick in the market.
• The advancements in gene editing technology by NTLA are seen as promising by investors, contributing to the increase in stock price.
• NTLA may have responded to a perceived edge by CRISPR Therapeutics (CRSP) by highlighting its own potential, resulting in the bullish market movement.

31.06.2025 - NTLA Stock was down 5.6%

• The bearish movement in NTLA stock today might be attributed to the following reasons:
• Investors may have had high expectations for the second quarter earnings call, leading to disappointment if the results did not meet projections.
• There could be concerns about the company's operational highlights discussed during the call, potentially indicating challenges or setbacks in their CRISPR-based therapies.
• The broader market sentiment towards genomics stocks might have shifted, impacting NTLA along with other companies in the sector.